Obesity and gut microbiome: review of potential role of probiotics

Francine Schütz, MSca, Margarida Figueiredo-Braga, PhDh,c, Pedro Barata, PhDh,e, Natália Cruz-Martins, PhDh,e,f,g

Abstract
Obesity prevalence has increased worldwide over the years, with pandemic levels being already reached, besides to its huge economic and health impacts. The multifactorial pathogenesis of obesity partly explains the important challenge posed to health policy regarding its clinical treatment, with increasing evidences have shown that obesity and metabolic disturbances are closely linked to variations in gut microbiota (GM) function and composition. Indeed, GM play a key contribution in energy metabolism, with GM modulation being increasingly linked to changes in body weight and body mass index. In such matter, probiotics have been proposed as a promising new therapeutic strategy to treat/prevent obesity. Thus, this review aims to provide an overview on the clinical impact and effectiveness of probiotics in obese individuals.

Keywords: gut microbiota, health promotion, inflammation, obesity, probiotics

Introduction
Obesity is a complex, multifactorial pathogenesis, where socioeconomic, hormonal and neuronal mechanisms, unhealthy lifestyle and genetic and epigenetic factors are involved. According to the World Health Organization, it is estimated that in 2035, 39% of the worldwide adult population will become obese. Evidences have proposed that obesity and associated metabolic disturbances are correlated to alterations in both gut microbiota (GM) function and composition, which have a crucial role in modulating the host’s energy metabolism. Indeed, recently published data have underlined the key determinant role of GM in host’s metabolic homeostasis and diseases’ onset. Indeed, it is a matter of fact that, to GM, a plethora of biological effects have been listed, such as impacting human physiology and pathology; influencing gut epithelial homeostasis; developing host’s immunity; modulating host’s nutritional status and energy uptake through, for example, producing vitamins and fermenting non-digestible dietary sources; protecting against pathogens; and even promoting drug metabolism. In addition, and namely to what concerns to the use of probiotics, they have emerged as a promising and safe therapy for different purposes in clinical practice. However, such effectiveness depends on the species and doses used, as well as on underlying disease, with duration of administration also impacting the final outcomes, these ones also varying according to the clinical indication.

Nonetheless, the way through whom GM is linked to obesity and metabolic syndrome, and the role of probiotics on both obesity and related consequences prevention and treatment is not yet fully elucidated. In this sense, this review aims to provide an overview on the clinical impact of probiotics in obese individuals (Figure 1).

Research methodology
To accomplish with the objective proposed a careful revision of the literature data published in the PubMed database, using “obesity”, “gut microbiota” and “probiotics” as keywords was done. Only clinical (randomized, cohort, case-control) studies published in English in the last 10 years, and addressing the role of probiotics in both obesity and/or metabolic syndrome prevention and treatment were included.

Gut microbiota and obesity
Briefly, obesity derives from the positive imbalance between energy intake and expenditure leading to a chronic metabolic disease linked to low-grade inflammation. Anyways, the raise in the prevalence of obesity has been mostly linked to socioeconomic factors, sedentary lifestyle and unhealthy dietary habits. However, recent knowledge has shown an increasing involvement of GM in promoting obesity. Indeed, GM is directly involved in ensuring a proper host’s immune function, metabolic activity and appears to also have a key role in the onset of some disorders.

Given that GM has a key role in the normal functioning of immune system and metabolic function, a GM imbalance (dysbiosis) may be viewed as a triggering factor for both metabolic and autoimmune diseases. In fact, numerous recent studies have clarified the association between body weight (BW)
maintenance and GM, and demonstrated that gut microbiome changes decrease BW and fat mass and ameliorate insulin sensitivity.12

In 2006, Turnbaugh et al, using a genetic model of obesity, revealed that when germ-free mice were colonized with either the microbiota from genetically obese (ob/ob) mice presented an elevated fat mass and BW.13 In fact, perturbations in gut microbiome composition in obese individuals have favored an increased energy harvest from food, and development of adiposity.14

Among the mechanisms capable of improving the host’s ability to extract energy from the diet is related to the microbiota’s ability to break down non-digestible dietary sources, generating short-chain fatty acids (SCFAs) and gases.15 As a consequence, SCFAs are able to promote a greater secretion of GLP-1 in the intestine, stimulating the release of insulin from the pancreas, delaying gastric emptying and, thus, promoting satiety and weight loss.16 In addition, butyrate, a type of SCFA, as the main source of energy for enterocytes, is also involved in the regulation of cell differentiation and proliferation and promotes the production of GLP-2, reducing intestinal permeability and increasing intestinal glucose transport,14 ultimately reducing inflammation and oxidative damage.17

In 2005, Ley et al demonstrated that obesity alters GM composition. Comparing the GM composition in genetically obese mice to lean counterparts, the authors stated a reduction in 50% in Bacteroidetes and a proportional increase in Firmicutes abundance.18 In addition, an increase in the number of Gram-negative species in GM has also been reported as a consequence of high-fat diets, promoting greater intestinal absorption of lipopolysaccharides, the increase of which is defined as “metabolic endotoxemia”. Indeed, some studies in animal models have demonstrated that endotoxemia leads to fasted hyperglycemia and hyperinsulinemia, BW gain, like to that found in high-fat-fed mice.19

On the other hand, metabolic endotoxemia has been correlated with a low level of intestinal inflammation, due to the interaction between host’s immune system and luminal bacteria.20 In fact, there have been studies highlighting the important role of inflammation in the main pathophysiological factors that lead to insulin resistance and, consequently, type 2 diabetes.20,21 In addition, high-fat diets have been shown to promote the growth of patobionts, triggering an innate immune mediated inflammatory response, that culminate with pro-inflammatory cytokines or toxic compounds production.

In addition to the effects described above, these mechanisms also enhance intestinal permeability, microbial molecules translocation and systemic inflammation. Likewise, saturated fatty acids, highly frequent in obesogenic diets, also promote the intestinal permeability by inducing innate immune receptors expression and activation and lymphocytes flow and proliferation.21

In humans, several studies have also demonstrated the relationship between variations in GM composition and obesity, where specific alterations in GM structure lead to a proportional increase of Firmicutes and to a decrease in Bacteroidetes phylum.22,23 Also, other studies have shown that subjects with low bacterial richness have higher C-reactive protein and leptin levels, dyslipidemia, insulin resistance, gain more weight and have higher adiposity and inflammatory phenotype comparing to that with high bacterial gene counts.23

In general, data have revealed that obese individuals have a GM featured by a decrease in anti-inflammatory bacteria and a raise in pathogens. Such changes trigger a pronounced decrease in SCFAs production, which ultimately impair intestinal barrier integrity and increase mucus degradation potential.25
**Probiotic as therapeutic target on obesity**

The impact of probiotics on health promotion has been increasingly evident, at the same time that the number of studies focusing on their therapeutic potential in certain diseases has also increased. In fact, its potential to stimulate the immune system has been highly appreciated, as well as its ability to exert a competitive effect against certain pathogens in addition to many other beneficial effects for the host. With regard specifically to the probiotics impact and effectiveness on obesity, an increasing number of clinical studies have been done in obese individuals with several associated comorbidities, as described in Table 1.

For example, in a 12-week study period performed in 2010, the administration of fermented milk containing *Lactobacillus gasseri* SBT2055 led to a marked reduction in visceral adipose tissue, BW and body mass index (BMI). A similar scenario was stated following administration of *L. curvatus* HY7601 and *L. plantarum* KY1032. In another study, overweight adults receiving *Bifidobacterium* spp. *lactis* 420 (B420) with or without fiber (Litesse Ultra polydextrose) for 6 months revealed a good control in body fat mass. A similar trend was stated following administration of a symbiotic formula containing *L. rhamnosus*, inulin and oligofructose, for 12 weeks, with weight loss being also recorded. Rajkumar et al using a high-dose mixture of probiotic strains of the *Lactobacillus*, *Bifidobacterium* and *Streptococcus* genus along with omega-3 fatty acid supplementation stated a marked improvement in GM composition, plasma lipids, insulin sensitivity, and inflammation markers in overweight adults. Besides that, the group who received the probiotic alone only demonstrated a positive alteration on GM, while omega-3 alone did not experienced any change. In abdominally obese individuals, the supplementation of *B animalis* subsp *lactis* CECT S145 (viable or heat-killed cells) for 3 months markedly improved BMI, waist circumference (WC) and WC/height ratio. Similar findings were stated after treatment with *heat-killed Pedicoccus pentosaceus* LP28 in overweight subjects. In such study, after 12 weeks, the participants showed a reduction in BMI, body fat and WC. Positive outcomes in decreasing body fat mass were also stated following treatment with *Bifidobacterium breve* B-3 in pre-obese adults after 12 weeks. Concomitantly, improvements in inflammation- and liver-function-related parameters were also listed. Such results were corroborated in another study in healthy pre-obese individuals where *B breve* B-3 led to body fat reduction. In such way, Kondo and colleagues, in a intend to describe the possible anti-obesity mechanisms of *B breve* B-3 underlined that they were triggered by intestinal barrier function improvement, B-3-derived metabolites (acetic and conjugated linoleic acids), and adiponectin and pro-glucagon production.

In hepatopathic obese children, the supplementation with high-dose *L rhamnosus* GG along with lifestyle intervention for 8 weeks led to a marked reduction in hypertransaminasemia. Similarly, another study in obese children with nonalcoholic fatty liver disease (NAFLD) stated that the administration of a probiotic mixture composed of *L. rhamnosus* DSMZ 21690, *L. acidophilus* ATCCB3208, *B bifidum* ATCCSD6576 and *B lactis* DSMZ 32269 for 12 weeks decreased aspartate transaminase, alanine aminotransferase, triglycerides, total cholesterol, and LDL-C levels, and WC. Other authors assessing the effect of *B pseudocatenulatum* CECT 7765 in insulin-resistant obese children over a 13-week period and reported a pronounced reduction in BW and improvement in inflammatory status.

Besides to the above-mentioned findings, probiotics have also revealed great abilities to reverse dysbiosis and normalize GM, which explain for example the protective effects reported in NAFLD patients (with endotoxemia and inflammation markers reduction). In addition, some probiotics have shown a great potential to reduce hepatic fat deposition, also exerting anti-fibrotic effects by modulating collagen expression and transforming growth factor-beta.

Another study carried out in obese and overweight women reported that the consumption of a yogurt commercially available (Streptococcus thermophilus and *L. bulgaricus*) enriched with *L. acidophilus* LA5 and *B lactis* BB12 for 12 weeks improved both lipid profile and insulin sensitivity. Indeed, there are increasing evidences reporting that probiotics can modify bile acid metabolism, which ultimately influences cholesterol absorption in the gut lumen. The hypocholesterolemic effect of probiotics can be explained by the fact that some bacterial species produced an enzyme, bile salt hydrolase, involved in the first reaction biliary salts deconjugation.

In obese women, the administration of a probiotic mix composed of *L acidophilus* LA-14, *L casei* LC-11, *L lactis* LL-23, and *B bifidum* BB-06, improved BW composition after an 8-week supplementation period. As main findings, the study group revealed a marked decrease in WC, WC/height ratio and conicity index, due to suppression of fasting-induced adipose factor in the gut, involved in SCFAs production. In fact, evidence has shown that SCFAs regulate energy metabolism by interaction with G protein-coupled receptors, thus modifying insulin sensitivity both in adipocytes and peripheral organs.

In obese pregnant women, *Vivomixx®* (a commercial product with 8 probiotic bacterial strains) promoted a control in weight gain. Besides that, the probiotic mix could reduce complications during pregnancy. Other study demonstrated that the daily intake of probiotics could impair the preeclampsia risk in primiparous women. Similarly, Asemi et al, demonstrated that the daily intake of a probiotic yoghurt promoted serum insulin levels maintenance and helped pregnant women from insulin resistance. Some other probiotic strains have also revealed great abilities to decrease glucose absorption and to improve insulin resistance through direct action on upregulated proglucagon expression, decreasing adiposity and inflammation status.

In obese postmenopausal women, the consumption of a probiotic mix Ecologic®, composed of 9 *Lactobacillus* and *Bifidobacterium* strains for 12 weeks ameliorated BW, BMI, visceral fat, and fat mass, although the most prominent changes were stated to the group receiving the high-dose probiotic. Interestingly, such changes in BW composition can be explained by the probiotic mix ability to decrease SCFAs accumulation through GPR43 interaction, resulting in an increased adipogenesis and leptin release and decreased lipolysis and inflammation.

Furthermore, the SCFAs interaction with G protein-coupled receptor lead to an enhanced satiety by raising the intestinal secretion of glucagon-like peptide 1 and polypeptide YY.

In morbid obese patients following gastric bypass surgery a probiotic supplement Familact® promoted BW loss and ameliorated pro-inflammatory biomarker (TNF-α) and vitamin D status. The possible mechanisms behind such effects appeared to be due to direct impact on gastrointestinal appetite hormones and gut microbiome composition, which ultimately modify both diet-harvested energy and promote host energy homeostasis.

De Lorenzo et al, in a 3-week supplementation period with a mixture including 10 different psychobiotics revealed a prominent modulation in BW composition. As main findings, psychobiotics
| Population studied | Intervention | Control/placebo group | Duration | Clinical findings | Reference |
|---------------------|--------------|-----------------------|----------|-------------------|-----------|
| Adults (33-63 yr): obese tendencies (n = 34) | Fermented milk containing L. gasseri SBT50055 | Fermented milk (200 g/d) without probiotic | 12 wk | ↓ Abdominal visceral, subcutaneous fat, BW and BMI | Kadowka et al.37 |
| Obese children (10-13 yr): hypertransaminasemia and ultrasonographic bright liver (n = 20); intervention (n = 10); placebo (n = 10) | L. rhamnosus GG (12 billion CFU/d) | 1 capsule/d placebo | 8 wk | ↑ Hypertransaminasemia, BMI and visceral fat | Vajro et al.54 |
| Obese adults (40-60 yr): omega-3 fatty acid (n = 15); probiotic VSL#3, (n = 15); omega-3 + probiotic (n = 15); placebo (n = 15) | SBL, SBT2055 Fermented milk (200 g/d) | 1 capsule/d placebo | 6 wk | ↓ TC, TG, LDL, VLDL, and hsCRP; ↑ HDL; insulin sensitivity, gut microbiota diversity | Vajro et al.54 |
| Obese adults (20-65 yr); intervention (n = 60); placebo (n = 60) | L. casei CRL1231 + and L. acidophilus LA-14, L casei LC-11, L lactis CC-241, B lactis BB-06 + dietary intervention | 2 capsules/d placebo + healthy lifestyle habits | 12 wk | ↓ Body fat mass, BMI and WC | Mirani et al.56 |
| Pre-obese adults (20-64 yr); intervention (n = 40); placebo (n = 40) | B. breve B-3 (5 billion CFU/d) | 1 capsule/d placebo | 12 wk | ↓ Body fat mass, BMI and WC | Mirani et al.56 |
| Pre-obese adults (20-64 yr); intervention (n = 40); placebo (n = 40) | B. breve B-3 | 1 capsule/d placebo | 3 mg | ↑ OAGB-MGB and zonulin level | Mirani et al.56 |
| Pre-obese adults (20-64 yr); intervention (n = 40); placebo (n = 40) | B. breve B-3 | 1 capsule/d placebo | 12 wk | ↑ BMI, WC after intervention II | Higashikawa et al.57 |
| Pre-obese adults (20-64 yr); random allocation (n = 120); intervention (n = 60); placebo (n = 60) | B. breve B-3 | 1 capsule/d placebo | 12 wk | ↓ TC, LDL, insulin resistance | Madjd et al.58 |
| Pre-obese adults (20-64 yr); intervention (n = 40); placebo (n = 40) | B. breve B-3 | 1 capsule/d placebo | 12 wk | ↑ WC and pregnancy complications | Hihkari et al.59 |
| Pre-obese adults (20-64 yr); intervention (n = 40); placebo (n = 40) | B. breve B-3 | 1 capsule/d placebo + dietary prescription | 8 wk | ↓ Weight | Gomes et al.52 |
| Pre-obese adults (20-64 yr); intervention (n = 40); placebo (n = 40) | B. breve B-3 | 1 capsule/d placebo | 12 wk | ↓ AAT, AAT, TC, LDL, TG, WC | Famour et al.60 |
| Pre-obese adults (20-64 yr); intervention (n = 40); placebo (n = 40) | B. breve B-3 | 1 capsule/d placebo | 12 wk | ↓ BMI, Fat mass, psychophatological scores, bacterial overgrowth and BUT GSI scale | De Lorenzo et al.61 |
| Pre-obese adults (20-64 yr); intervention (n = 40); placebo (n = 40) | B. breve B-3 | 1 capsule/d placebo | 12 wk | ↑ Free fat mass, meteorism and defecation frequency | Sanchis-Chordà et al.62 |
| Pre-obese adults (20-64 yr); intervention (n = 40); placebo (n = 40) | B. breve B-3 | 1 capsule/d placebo | 12 wk | ↑ Body fat mass | Minami et al.63 |
| Pre-obese adults (20-64 yr); intervention (n = 40); placebo (n = 40) | B. breve B-3 | 1 capsule/d placebo | 12 wk | ↑ Body fat mass | Stulhkiska et al.64 |

BMI = body mass index; BW = body weight; CFU = colony-forming units; GLP-1 = glucagon-like peptide-1; HDL = high density lipoprotein; hsCRP = high-sensitivity C reactive protein; LDL = low density lipoprotein; OAGB-MGB = one anastomosis gastric bypass-mini gastric bypass; OA = omega-3 fatty acid; TC = total cholesterol; TG = triglycerides; VLDL = very low density lipoprotein; WC = waist circumference.
led to a pronounced reduction in BMI, resistance and fat mass, and to an increase in free fat mass, along with a decrease in bacterial overgrowth and psychopathological scores.53

Also of worth of note is that the microbiota-gut-brain axis, while a bidirectional communication pathway between GM and brain,54 have been target of a high attention. Indeed, increasing evidence have shown that GM exerts a crucial role in both mood and behavior regulation, besides GM modulation.55,56 For example, Di Renzo et al, found an association between BW composition and eating behavior in normal weight obese patients, which appears to be related to their ability to mitigate anxiety symptoms and improve eating behavior, ultimately contributing to weight loss.57

In short, taking into account the currently available clinical data, probiotic supplementation seems to be useful to improve specific anthropometric, biochemical and inflammatory parameters, although the absence of some consistent data, of detailed information related to the different probiotic strains used, and lack of long-term follow-up and high sample size studies limit the establishment of more solid conclusions.

Conclusions

Intestinal microbiota has a preponderant role in both modulating fat deposition and energy homeostasis, as well as in the host’s relationship with environmental factors. Recent data have revealed that thin individuals have an intestinal microbiota composition completely different from that observed in obese individuals, which directly relate dysbiosis to the greater propensity to obesity and linked metabolic disorders. In addition, more and more studies are showing the beneficial effects of the consumption of probiotics in maintaining BMI, BW, fat mass, WC, lipid profile and inflammatory status. Taken together, these data point to new horizons regarding intervention on obesity and related metabolic disorders, despite more studies are needed to assertively assess the effect of a plethora of probiotic strains or symbiotic preparations for both health promotion and treatment.

Acknowledgements

N.M. acknowledges the Portuguese Foundation for Science and Technology under the Horizon 2020 Project (PTDC/PSI-GER/2017).02299/2017).

Conflicts of interest

Authors have declared no conflict of interest.

References

[1] Cerdó T, García-Santos JA, GBermejo M, Caspoy C. The role of probiotics and prebiotics in the prevention and treatment of obesity. Nutrients. 2019;11:635.
[2] Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:xi; 1–253.
[3] Festi D, Schiumerini R, Eusebi LH, Marasco G, Taddia M, Colechia A. Gut microbiota and metabolic syndrome. World J Gastroenterol. 2014;20:16079–16094.
[4] Saklany MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep. 2018;20.12.
[5] Cani PD, Delzenne NM. Gut microbiota as a target for energy and metabolic homeostasis. Curr Opin Clin Nutr Metab Care. 2007;10:729–734.
[6] Sanz Y, Olivares M, Moya-Pérez A, Agostoni C. Understanding the role of gut microbiome in metabolic disease risk. Pediatr Res. 2015;77:2–126–244.
[7] Salehi B, Dimitrijević M, Aleksić A, et al. Human microbiome and homeostasis: insights into the key role of probiotics, prebiotics, and symbiotics. Crit Rev Food Sci Nutr. 2020;13:1–14.
[8] Shariﬁ-Rad J, Rodrigues CF, Stronajnović-Radić Z, et al. Probiotics: versatile bioactive components in promoting human health. Medicina (Kaunas). 2020;56:643.
[9] Green M, Arora K, Prakash S. Microbial medicine: probiotic and probiotic functional foods to target obesity and metabolic syndrome. Int J Mol Sci. 2020;21:2890.
[10] Elluha MS, Patimah I, Khaza’a H, Rahmat A, Abed Y. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci. 2017;13:S1–S63.
[11] Abenavoli L, Scarpellini E, Colica C, Boccuti L, Salehi B, Shariﬁ-Rad J, Aiello V, Romano B, De Lorenzio A, Izzo AA, Capasso R. Gut microbiota and obesity: a role for probiotics. Nutrients. 2019;11:21699.
[12] Rastelli M, Knasf C, Cani PD. Gut microbes and health: a focus on the mechanisms linking microbes, obesity, and related disorders. Obesity (Silver Spring). 2018;26:792–800.
[13] Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JJ. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444:1027–1031.
[14] Turnbaugh PJ, Bäckhed F, Fulton L, Gordon JJ. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe. 2008;3:213–223.
[15] Larrau ﬂ, Peiri-Gallauziaux C, Lapaque N, et al. SCFAs strongly stimulate PYY production in human enteroreendoendocrine cells. Sci Rep. 2018;8:74.
[16] Cani PD, Posseniers S, Van de Wiele T, et al. Changes in gut microbiota control inﬂammation in obese mice through a mechanism involving GEP-2 drove development of gut permeability. Gut. 2005;58:1091–1103.
[17] Singh RK, Chang HW, Yan D, et al. Inﬂuence of diet on the gut microbiome and implications for human health. J Transl Med. 2017;15:73.
[18] Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JJ. Obesity alters gut microbial ecology. Proc Natl Acad Sci USA. 2006;103:11070–11075.
[19] Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761–1772.
[20] de la Serre CB, Ellis CL, Lee J, Hartman AL, Rutledge JC, Raybould HE. Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inﬂammation. Am J Physiol Gastrointest Liver Physiol. 2010;299:G440–G448.
[21] Kim KA, Gu W, Lee IA, Jho EH, Kim DH. High fat diet-induced gut microbiota exacerbates inﬂammation and obesity in mice via the TLR4 signaling pathway. PLoS One. 2012;7:e47713.
[22] Devkota S, Wang X, Musch MW, et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in IL10−/− mice. Nature. 2012;487:104–108.
[23] Armougom F, Henry M, Vaelettes B, Raccah D, Rasolat. Monitoring bacterial community of human gut microbiota reveals an increase in Lactobacillus in obese patients and Methanogens in anorexic patients. PLoS One. 2009;4:e7125.
[24] Santacruz A, Collado MC, García-Valdes L, et al. Gut microbiota composition is associated with body weight, weight gain and biochemical parameters in pregnant women. Br J Nutr. 2010;104:81–92.
[25] Le Chatelier E, Nielsen T, Qin J, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500:541–546.
[26] Hill C, Guarner F, Reid G, et al. Expert consensus document. The International Scientiﬁc Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11:506–514.
[27] Kadooka Y, Sato M, Imazumi K, et al. Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial. Eur J Clin Nutr. 2010;64:636–643.
[28] Ahn HY, Kim M, Chae JS, et al. Supplementation with two probiotic strains, Lactobacillus curvatus H7601 and Lactobacillus plantarum KY1032, reduces fasting triglycerides and enhances apolipoprotein A-V levels in non-diabetic subjects with hypertriglyceridemia. Atherosclerosis. 2015;241:649–656.
[29] Stenman LK, Lehtinen MJ, Meland N, et al. Probiotic with or without fiber controls body fat mass, associated with serum zonulin, in overweight and obese adults randomized controlled trial. EbioMedicine. 2016;13:190–200.
[30] Sanchez M, Darimont C, Panahi S, et al. Effects of a diet-based weight-reducing program with probiotic supplementation on satiety efficiency,
eating behaviour traits, and psychosocial behaviours in obese individuals. Nutrients. 2017;9:284.
[31] Rajkumar H, Mahmood N, Kumar M, Varikuti SR, Challa HR, Miyakawa SP. Effect of probiotic (VSL#3) and omega-3 on lipid profile, insulin sensitivity, inflammatory markers, and gut colonization in overweight adults: a randomized, controlled trial. Mediators Inflamm. 2014;2014:348959.
[32] Pedret A, Valls RM, Calderón-Pérez L, et al. Effects of daily consumption of the probiotic Bifidobacterium animalis subs p. lactis CECT 8145 on anthropometric adiposity biomarkers in abdominally obese subjects: a randomized controlled trial. Int J Obes (Lond). 2019;43:1863-1868.
[33] Higashikawa F, Noda M, Awaya T, et al. Antioxidant effect of Pediococcus pentosaceus LP28 on overweight subjects: a randomized, double-blind, placebo-controlled clinical trial. Eur J Clin Nutr. 2016;70:582-587.
[34] Minami J, Iwabuchi N, Tanaka M, et al. Effects of Bifidobacterium breve B-3 on body fat reductions in pre-obese adults: a randomized, double-blind, placebo-controlled trial. Biosci Microbiota Food Health. 2018;37:67-75.
[35] Kondo S, Xiao J, Satoh T, et al. Antiobesity effects of Bifidobacterium breve strain B-3 supplementation in a mouse model with high-fat diet-induced obesity. Biosci Biotechnol Biochem. 2010;74:1656-1661.
[36] Vajro P, Mandato C, Licenziati MR, et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr. 2011;52:740-743.
[37] Famouri F, Shariat Z, Hashemipour M, Keikha M, Kelishadi R. Effects of the probiotic Biobacterium breve B-3 modulates metabolic functions in adults with obese tendencies in a randomised controlled trial. J Nutr Sci. 2015;4:e17.
[38] Minami J, Iwabuchi N, Tanaka M, et al. Effects of Bifidobacterium breve B-3 on insulin sensitivity, in overweight adults: a randomized, controlled trial. Mediators Inflamm. 2017;2017:1895.
[39] Brantsaeter AL, Myhre R, Haugen M, et al. Intake of probiotic food and risk of preeclampsia in primiparous women: the Norwegian Mother and Child Cohort Study. Am J Epidemiol. 2011;174:807-815.
[40] Xie C, Halegoua-DeMarzio D. Role of probiotics in non-alcoholic fatty liver disease. Proc Natl Acad Sci USA. 2004;101:15718-15723.
[41] Cantfora EE, Jocken JW, Blaak EE. Short-chain fatty acids in control of body weight and insulin sensitivity. Nat Rev Endocrinol. 2015;11:577-591.
[42] Hallají S, Nilas L, Carlsen EM, et al. Effects of probiotics (Vivomixx®) in obese pregnant women and their newborn: study protocol for a randomized controlled trial. Trials. 2016;17:491.
[43] Brantsaeter AL, Myhre R, Haugen M, et al. Intake of probiotic food and risk of preeclampsia in primiparous women: the Norwegian Mother and Child Cohort Study. Am J Epidemiol. 2011;174:807-815.
[44] Bäckhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA. 2004;101:15718-15723.